CHANGES IN DYSPNEA-FATIGUE RATINGS AS INDICATORS OF QUALITY OF LIFE IN THE TREATMENT OF CONGESTIVE HEART-FAILURE
CHANGES IN DYSPNEA-FATIGUE RATINGS AS INDICATORS OF QUALITY OF LIFE IN THE TREATMENT OF CONGESTIVE HEART-FAILURE
复制标题
DOI：
10.1016/0002-9149(89)90652-8
复制
发表时间：
1989-07-01
影响因子：
2.8
通讯作者：
PIGEON, JG
中科院分区：
文献类型：
--
作者：
FEINSTEIN, AR;FISHER, MB;PIGEON, JG
一种新的临床指标呼吸困难和疲劳已被应用于评估充血性心力衰竭患者的病情。该指数有3个组成部分，每个组成部分的评分范围为0 - 4，分别是引起呼吸困难或疲劳的任务的强度、执行任务的速度（或努力）的强度以及一般活动中的相关功能障碍。将每个组件的评级相加以形成汇总分数，其范围可以从最差条件的0到最佳条件的12。由于呼吸困难和疲劳是临床痛苦的主要症状和来源，该指数有助于反映充血性心力衰竭患者的生活质量。在治疗的双盲试验中，该指数的变化与患者自我选择的改善评级显示出良好的相关性。新活性药物（赖诺普利）治疗后指数评分的变化显著高于安慰剂或另一种活性药物（卡托普利）。
A new clinical index of dyspnea and fatigue has been applied to rate the condition of patients with congestive heart failure. The index has 3 components, each rated on a scale from 0 to 4, for the magnitude of the task that evokes dyspnea or fatigue, the magnitude of the pace (or effort) with which the task is performed and the associated functional impairment in general activities. The ratings for each component are added to form an aggregated score, which can range from 0, for the worst condition, to 12, for the best. Because dyspnea and fatigue are prime symptoms and sources of clinical distress, the index helps reflect the quality of life in patients with congestive heart failure. In double-blind trials of therapy, changes in the index showed good correlations with patients'' self-selected ratings of improvement. The posttherapeutic changes in the index ratings were significantly higher with a new active agent (lisinopril) than with placebo or another active agent (captopril).